P2RY14

Summary

P2RY14 (purinergic receptor P2Y14, HGNC:16442) is a protein-coding gene on chromosome 3q25.1, encoding P2Y purinoceptor 14 (Q15391). Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins.

The product of this gene belongs to the family of G-protein coupled receptors, which contains several receptor subtypes with different pharmacological selectivity for various adenosine and uridine nucleotides. This receptor is a P2Y purinergic receptor for UDP-glucose and other UDP-sugars coupled to G-proteins. It has been implicated in extending the known immune system functions of P2Y receptors by participating in the regulation of the stem cell compartment, and it may also play a role in neuroimmune function. Two transcript variants encoding the same protein have been identified for this gene.

Source: NCBI Gene 9934 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 2 total
• Druggable target: yes
• MANE Select transcript: NM_014879

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16442
Approved symbol	P2RY14
Name	purinergic receptor P2Y14
Location	3q25.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0001
Ensembl gene	ENSG00000174944
Ensembl biotype	protein_coding
OMIM	610116
Entrez	9934

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 protein_coding

ENST00000309170, ENST00000424796, ENST00000494668, ENST00000908303, ENST00000908304, ENST00000908305, ENST00000908306, ENST00000908307, ENST00000908308, ENST00000908309, ENST00000908310, ENST00000945445, ENST00000945446, ENST00000945447

RefSeq mRNA: 2 — MANE Select: NM_014879 NM_001081455, NM_014879

CCDS: CCDS3156

Canonical transcript exons

ENST00000309170 — 3 exons

Exon	Start	End
ENSE00001208977	151219535	151219642
ENSE00001208984	151278287	151278542
ENSE00001208990	151212117	151214340

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 97.33.

FANTOM5 (CAGE): breadth broad, TPM avg 1.7816 / max 122.6493, expressed in 258 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45135	0.8704	123
45139	0.4166	152
45136	0.2913	92
45128	0.0459	21
45131	0.0418	16
45130	0.0350	21
45129	0.0303	19
45140	0.0205	8
45133	0.0202	10
45132	0.0096	3

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	97.33	gold quality
skin of hip	UBERON:0001554	90.51	gold quality
endothelial cell	CL:0000115	89.95	gold quality
synovial joint	UBERON:0002217	89.89	gold quality
upper leg skin	UBERON:0004262	89.45	gold quality
calcaneal tendon	UBERON:0003701	87.51	gold quality
endometrium	UBERON:0001295	87.03	gold quality
mucosa of stomach	UBERON:0001199	85.70	gold quality
colonic epithelium	UBERON:0000397	83.42	gold quality
visceral pleura	UBERON:0002401	82.96	gold quality
placenta	UBERON:0001987	82.88	gold quality
upper arm skin	UBERON:0004263	82.77	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.75	gold quality
caecum	UBERON:0001153	82.42	gold quality
right lung	UBERON:0002167	82.42	gold quality
buccal mucosa cell	CL:0002336	82.36	gold quality
rectum	UBERON:0001052	81.90	gold quality
vermiform appendix	UBERON:0001154	81.70	gold quality
fundus of stomach	UBERON:0001160	80.47	gold quality
pleura	UBERON:0000977	80.38	gold quality
dorsal root ganglion	UBERON:0000044	80.33	gold quality
mammalian vulva	UBERON:0000997	79.90	gold quality
superficial temporal artery	UBERON:0001614	79.80	silver quality
cardia of stomach	UBERON:0001162	79.47	gold quality
mucosa of sigmoid colon	UBERON:0004993	79.30	gold quality
oral cavity	UBERON:0000167	79.26	gold quality
lower lobe of lung	UBERON:0008949	79.16	gold quality
parietal pleura	UBERON:0002400	78.77	gold quality
transverse colon	UBERON:0001157	78.27	gold quality
body of stomach	UBERON:0001161	78.10	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	462.46
E-MTAB-6701	yes	115.20
E-MTAB-8498	yes	13.50
E-CURD-112	yes	12.70
E-HCAD-11	yes	9.14
E-MTAB-9801	yes	6.78
E-ANND-3	yes	4.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

89 targeting P2RY14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-373-3P	99.84	70.68	1668
HSA-MIR-520E-3P	99.84	70.55	1698
HSA-MIR-372-3P	99.83	70.58	1691
HSA-MIR-520A-3P	99.83	70.59	1687
HSA-MIR-520B-3P	99.83	70.56	1699
HSA-MIR-520C-3P	99.83	70.56	1699
HSA-MIR-520D-3P	99.83	70.78	1676
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4307	99.82	70.45	3374

Literature-anchored findings (GeneRIF, showing 15)

• The IUPHAR Subcommittee for P2Y receptor nomenclature and classification reviews the current knowledge of the UDP-glucose receptor and presents reasons for including it in the P2Y receptor family as the P2Y(14) receptor. (PMID:12559763)
• a G-protein-coupled receptor identifying a quiescent, primitive population of hematopoietic cells restricted to bone marrow; it mediates primitive cell responses to specific hematopoietic microenvironments (PMID:12842911)
• Discrete expression of GPR105 demonstrated within the immature subset of monocyte-derived dendritic cells (DC) suggests a possible role for this receptor in DC activation. (PMID:12902497)
• We have demonstrated the presence of P2Y(14) receptor protein in platelets, but no contribution of this receptor to several measures of platelet function has been observed (PMID:18690346)
• UDP-glucose stimulated IL-8 production via P2RY14 in human endometrial epithelial cells but not stromal cells (PMID:19454705)
• These results support the notion that UDP-glucose is a stable and potent proinflammatory mediator that promotes P2Y(14)-R-mediated neutrophil motility via Rho/Rho kinase activation. (PMID:22673622)
• PPTN as a highly selective high-affinity antagonist of the P2Y14-R. (PMID:23592514)
• UDP-glucose activates P2Y14 receptor and JAK2, increases STAT3 Tyr705 phosphorylation, and enhances transcription of HAS2. (PMID:24847057)
• Data show that thymidine 5’-O-monophosphorothioate (TMPS) diminished UDPG-evoked intracellular calcium mobilization in a stable HEK293T cell line overexpressing the P2Y14 receptor. (PMID:27732965)
• Present study suggests that P2Y14 expression could be used as a phenotypic marker to further dissect placental HSPCs. (PMID:28804125)
• P2Y14R is downregulated in hCPCs derived from heart failure patients. Augmenting P2Y14R expression levels in aged/diseased hCPCs antagonizes senescence and improves functional responses. (PMID:28980705)
• UDP-glucose, a cellular danger signal, and nucleotide receptor P2Y14 enhance the invasion of human extravillous trophoblast cells. (PMID:33011563)
• P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inflammation. (PMID:33575962)
• The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver. (PMID:35385339)
• Expression of the pro-inflammatory P2Y14 receptor in the non-vasectomized and vasectomized human epididymis. (PMID:36029226)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	P2RY14	ENSDARG00000103305
mus_musculus	P2ry14	ENSMUSG00000036381
rattus_norvegicus	P2ry14	ENSRNOG00000013872

Paralogs (6): GPR87 (ENSG00000138271), P2RY12 (ENSG00000169313), PTAFR (ENSG00000169403), GPR34 (ENSG00000171659), GPR171 (ENSG00000174946), P2RY13 (ENSG00000181631)

Protein

Protein identifiers

P2Y purinoceptor 14 — Q15391 (reviewed: Q15391)

Alternative names: G-protein coupled receptor 105, UDP-glucose receptor

All UniProt accessions (3): Q15391, A5JUU3, C9JAB5

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins. Not activated by ATP, ADP, UTP or ATP.

Subcellular location. Cell membrane.

Tissue specificity. Highest expression in the placenta, adipose tissue, stomach and intestine, intermediate levels in the brain, spleen, lung and heart, lowest levels in the kidney.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (2): NP_001074924, NP_055694* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR005466	P2Y14_rcpt	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain

Pfam: PF00001

UniProt features (21 total): topological domain 8, transmembrane region 7, glycosylation site 2, chain 1, disulfide bond 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
9J0F	ELECTRON MICROSCOPY	2.76
9J0I	ELECTRON MICROSCOPY	2.76
9J0B	ELECTRON MICROSCOPY	2.88
9YDV	ELECTRON MICROSCOPY	3.05
9YDU	ELECTRON MICROSCOPY	3.19
9J05	ELECTRON MICROSCOPY	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15391-F1	87.44	0.69

Antibody-complex structures (SAbDab): 4 — 9J05, 9J0B, 9J0I, 9YDU

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 94–172

Glycosylation sites (2): 3, 161

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-417957	P2Y receptors
R-HSA-418594	G alpha (i) signalling events

MSigDB gene sets: 279 (showing top): WALLACE_PROSTATE_CANCER_RACE_UP, GOBP_G_PROTEIN_COUPLED_PURINERGIC_NUCLEOTIDE_RECEPTOR_SIGNALING_PATHWAY, MODULE_64, REACTOME_P2Y_RECEPTORS, MODULE_289, WONG_ENDMETRIUM_CANCER_DN, DELYS_THYROID_CANCER_DN, KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION, MODULE_123, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_DN, WANG_TARGETS_OF_MLL_CBP_FUSION_UP, GOBP_PURINERGIC_NUCLEOTIDE_RECEPTOR_SIGNALING_PATHWAY, GOBP_MULTICELLULAR_ORGANISMAL_LEVEL_HOMEOSTASIS, HOEBEKE_LYMPHOID_STEM_CELL_UP, HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN

GO Biological Process (4): G protein-coupled receptor signaling pathway (GO:0007186), hematopoietic stem cell homeostasis (GO:0061484), signal transduction (GO:0007165), G protein-coupled purinergic nucleotide receptor signaling pathway (GO:0035589)

GO Molecular Function (3): G protein-coupled purinergic nucleotide receptor activity (GO:0045028), G protein-coupled UDP receptor activity (GO:0045029), G protein-coupled receptor activity (GO:0004930)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Nucleotide-like (purinergic) receptors	1
GPCR downstream signalling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor activity	2
signal transduction	1
homeostasis of number of cells	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
purinergic nucleotide receptor signaling pathway	1
purinergic nucleotide receptor activity	1
G protein-coupled purinergic nucleotide receptor signaling pathway	1
G protein-coupled pyrimidinergic nucleotide receptor activity	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

718 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
P2RY14	P2RX1	P51575	893
P2RY14	P2RX6	O15547	731
P2RY14	P2RX5	Q93086	723
P2RY14	P2RX2	Q9UBL9	715
P2RY14	P2RX3	P56373	665
P2RY14	P2RX4	Q99571	635
P2RY14	ALDH18A1	P54886	577
P2RY14	P2RY12	Q9H244	546
P2RY14	P2RX7	Q99572	526
P2RY14	ENTPD1	P49961	523
P2RY14	CD38	P28907	492
P2RY14	ADORA3	P0DMS8	492
P2RY14	PPBP	P02775	491
P2RY14	P2RY1	P47900	480
P2RY14	PTGER3	P43115	470

IntAct

3 interactions, top by confidence:

A	B	Type	Score
P2RY14	ATP12A	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (6): ATP12A (Affinity Capture-MS), APOB (Affinity Capture-MS), RAP2A (Affinity Capture-MS), ATP12A (Affinity Capture-MS), ATP12A (Affinity Capture-MS), P2RY14 (Affinity Capture-MS)

ESM2 similar proteins: B5X337, D4A4Q2, D4A7K7, O00398, O14626, O35881, P21556, P25105, P32249, P43657, P60019, Q15391, Q1RMI1, Q2NNR5, Q3SAG9, Q3SX17, Q3U507, Q3U6B2, Q3UJF0, Q3ZBK9, Q4G072, Q5ZI82, Q6XCF2, Q80Z39, Q8BFU7, Q8BG55, Q8BLG2, Q8BMC0, Q920A1, Q924T8, Q924T9, Q95KC3, Q95N02, Q95N03, Q99677, Q99JA4, Q99MT7, Q9BXC1, Q9BY21, Q9CPV9

Diamond homologs: D4A4Q2, O14626, O35881, P30992, P32250, Q15391, Q3SX17, Q3ZBK9, Q6GUG4, Q8BG55, Q95KC3, Q99MT7, Q9BE53, Q9BPV8, Q9BY21, Q9CPV9, Q9D8I2, Q9EPX4, Q9ESG6, Q9H244, O00254, P25105, Q28553, P60019, Q05394, Q3SAG9, Q6XCF2, Q9R1K6, Q9UPC5, B0UXR0, C8YUV0, E9QJ73, O02213, O08786, O09047, O16020, O42179, O55197, O57422, O70129

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
P2RY14	“up-regulates activity”	GNAI1	binding
P2RY14	“up-regulates activity”	GNAI3	binding
P2RY14	“up-regulates activity”	GNAO1	binding
P2RY14	“up-regulates activity”	GNAZ	binding
P2RY14	“up-regulates activity”	GNA14	binding
UDP-D-glucose	“up-regulates activity”	P2RY14	“chemical activation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1090 predictions. Top by Δscore:

Variant	Effect	Δscore
3:151268942:T:TA	donor_gain	0.9900
3:151278281:TCTTA:T	donor_loss	0.9900
3:151278282:CTTA:C	donor_loss	0.9900
3:151278283:TTA:T	donor_loss	0.9900
3:151278284:TA:T	donor_loss	0.9900
3:151278285:A:AT	donor_loss	0.9900
3:151214341:C:CC	acceptor_gain	0.9800
3:151248978:C:CT	acceptor_gain	0.9800
3:151248979:A:T	acceptor_gain	0.9800
3:151278502:G:GT	donor_gain	0.9800
3:151214342:T:G	acceptor_loss	0.9700
3:151234707:A:AG	donor_gain	0.9700
3:151278286:CCTG:C	donor_gain	0.9700
3:151278285:A:AC	donor_gain	0.9600
3:151278286:C:CC	donor_gain	0.9600
3:151214336:GAGGC:G	acceptor_gain	0.9500
3:151214339:GC:G	acceptor_gain	0.9500
3:151214340:CC:C	acceptor_gain	0.9500
3:151214338:GGC:G	acceptor_gain	0.9400
3:151223727:CT:C	donor_gain	0.9400
3:151277952:CACAT:C	donor_gain	0.9400
3:151214344:AAAAG:A	acceptor_loss	0.9300
3:151214345:AAAGA:A	acceptor_loss	0.9300
3:151219641:TC:T	acceptor_gain	0.9300
3:151219642:CC:C	acceptor_gain	0.9300
3:151277960:CGAG:C	donor_gain	0.9300
3:151214343:GAAAA:G	acceptor_loss	0.9200
3:151220778:T:A	acceptor_gain	0.9200
3:151272915:T:G	donor_gain	0.9200
3:151219639:GATCC:G	acceptor_loss	0.9000

AlphaMissense

2238 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:151213969:G:C	S116R	0.997
3:151213969:G:T	S116R	0.997
3:151213971:T:G	S116R	0.997
3:151213579:A:C	F246L	0.994
3:151213579:A:T	F246L	0.994
3:151213581:A:G	F246L	0.994
3:151213574:G:C	P248R	0.993
3:151213584:A:G	C245R	0.993
3:151213881:A:G	W146R	0.993
3:151213881:A:T	W146R	0.993
3:151214138:A:G	L60P	0.993
3:151213574:G:T	P248H	0.992
3:151213770:A:G	W183R	0.992
3:151213770:A:T	W183R	0.992
3:151213452:A:G	C289R	0.991
3:151213732:G:C	F195L	0.991
3:151213732:G:T	F195L	0.991
3:151213734:A:G	F195L	0.991
3:151213779:C:G	G180R	0.991
3:151213779:C:T	G180R	0.991
3:151214036:C:G	C94S	0.991
3:151214037:A:T	C94S	0.991
3:151213980:C:G	G113R	0.990
3:151213980:C:T	G113R	0.990
3:151213442:G:C	P292R	0.989
3:151213442:G:T	P292H	0.989
3:151213790:T:A	K176I	0.989
3:151213802:C:G	C172S	0.989
3:151213803:A:T	C172S	0.989
3:151213993:G:C	S108R	0.989

dbSNP variants (sampled 300 via entrez): RS1000049511 (3:151276390 A>G), RS1000063757 (3:151237579 G>A), RS1000091648 (3:151270171 T>C), RS1000102806 (3:151265184 A>G), RS1000245847 (3:151246811 A>G), RS1000307801 (3:151219233 T>G), RS1000315069 (3:151258027 T>C), RS1000331811 (3:151276463 T>C), RS1000361948 (3:151218763 A>T), RS1000366101 (3:151270084 AGAT>A), RS1000519932 (3:151237330 G>A,T), RS1000550293 (3:151241601 G>A), RS1000602410 (3:151241367 G>A,T), RS1000709801 (3:151247059 G>A,T), RS1000761730 (3:151252324 G>A)

Disease associations

OMIM: gene MIM:610116 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006479_120	Diverticular disease	9.000000e-11
GCST90002381_192	Eosinophil count	1.000000e-09
GCST90002407_414	White blood cell count	2.000000e-15

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009959	diverticular disease
EFO:0004842	eosinophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4518 (SINGLE PROTEIN), CHEMBL4524011 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — P2Y receptors

Most potent curated ligand interactions (22 total), top 22:

Ligand	Action	Affinity	Parameter
PPTN	Antagonist	10.1	pKi
MRS4174	Antagonist	10.1	pKi
P2Y14R antagonist I-17	Antagonist	9.22	pIC50
α.β-methylene-2-thio-UDP	Full agonist	9.04	pEC50
MRS4183	Agonist	9.02	pEC50
MRS2905	Agonist	9.0	pEC50
2-thio-UDP	Full agonist	8.72	pEC50
MRS4738	Antagonist	8.51	pIC50
MRS4833	Antagonist	8.23	pIC50
MRS4654	Antagonist	7.82	pIC50
compound A [PMID: 40037063]	Antagonist	7.63	pIC50
MRS4625	Antagonist	7.56	pIC50
MRS2690	Agonist	7.31	pEC50
UDP-glucuronic acid	Full agonist	7.2	pEC50
MRS2802	Agonist	7.2	pEC50
α,β-difluoromethylene-UDP	Agonist	7.2	pEC50
UDP	Full agonist	7.13	pEC50
UDP-glucose	Full agonist	7.1	pIC50
UDP-galactose	Full agonist	7.0	pEC50
MRS4458	Antagonist	6.77	pIC50
MRS4478	Antagonist	6.57	pIC50
UDP N-acetyl-glucosamine	Full agonist	6.0	pEC50

Binding affinities (BindingDB)

7 measured of 7 human assays (7 total across all organisms); most potent 7 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methyl-phenyl)urea	KD	450 nM
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide	KD	1100 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM
CHEMBL5437512	IC50	25900 nM

ChEMBL bioactivities

426 potent at pChembl≥5 of 451 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.10	Ki	0.08	nM	CHEMBL4447162
10.10	Ki	0.08	nM	CHEMBL5271821
10.10	Ki	0.08	nM	CHEMBL6165236
9.96	Kd	0.11	nM	CHEMBL5557370
9.40	IC50	0.4	nM	PPTN
9.40	IC50	0.4	nM	CHEMBL5561048
9.37	Ki	0.43	nM	PPTN
9.30	IC50	0.5	nM	PPTN
9.30	IC50	0.5	nM	CHEMBL4743495
9.26	IC50	0.55	nM	CHEMBL5568116
9.22	IC50	0.6	nM	CHEMBL5557370
9.15	IC50	0.7	nM	CHEMBL6169785
9.08	IC50	0.84	nM	CHEMBL6163632
9.04	EC50	0.92	nM	CHEMBL611791
8.96	IC50	1.1	nM	CHEMBL5517984
8.89	IC50	1.3	nM	CHEMBL5537095
8.89	IC50	1.29	nM	CHEMBL5561440
8.89	IC50	1.3	nM	CHEMBL6164437
8.82	IC50	1.52	nM	CHEMBL5561910
8.75	IC50	1.77	nM	CHEMBL4436879
8.72	IC50	1.9	nM	CHEMBL5558182
8.72	EC50	1.92	nM	CHEMBL216011
8.71	IC50	1.93	nM	CHEMBL5208130
8.70	IC50	1.98	nM	PPTN
8.70	IC50	2	nM	CHEMBL5186555
8.70	IC50	2	nM	PPTN
8.66	IC50	2.18	nM	CHEMBL4854775
8.64	Ki	2.3	nM	PPTN
8.64	Ki	2.3	nM	CHEMBL4743495
8.58	IC50	2.63	nM	CHEMBL4858280
8.53	IC50	2.95	nM	CHEMBL4875670
8.51	IC50	3.11	nM	CHEMBL5085823
8.50	IC50	3.17	nM	CHEMBL4577585
8.47	IC50	3.4	nM	PPTN
8.46	Ki	3.44	nM	CHEMBL5399275
8.42	IC50	3.83	nM	CHEMBL5194881
8.42	IC50	3.81	nM	CHEMBL5203559
8.42	IC50	3.8	nM	CHEMBL5532171
8.40	IC50	4.01	nM	CHEMBL5182459
8.40	IC50	3.97	nM	CHEMBL5561359
8.40	IC50	4.01	nM	CHEMBL5568047
8.38	IC50	4.16	nM	CHEMBL5175291
8.38	IC50	4.2	nM	CHEMBL5561561
8.36	IC50	4.35	nM	CHEMBL4538561
8.34	IC50	4.54	nM	CHEMBL4455311
8.33	IC50	4.66	nM	CHEMBL5192153
8.33	IC50	4.65	nM	CHEMBL5189241
8.32	IC50	4.8	nM	CHEMBL5193065
8.32	IC50	4.83	nM	CHEMBL5185002
8.32	IC50	4.8	nM	PPTN

PubChem BioAssay actives

382 with measured affinity, of 902 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[4-[1-[4-[1-[6-[[4-(3-amino-6-imino-4,5-disulfoxanthen-9-yl)-3-carboxybenzoyl]amino]hexyl]triazol-4-yl]butyl]piperidin-4-yl]phenyl]-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	1551934: Inhibition of human P2Y14 receptor expressed in CHO cells by fluorescence assay	ki	0.0001	uM
N-(3H-benzimidazol-5-yl)-2-(4-bromophenoxy)acetamide	2078096: Binding affinity to NHS-LC-biotin-labeled P2Y14R (unknown origin) immobilized in SSA sensor assessed as dissociation constant by BLI assay	kd	0.0001	uM
4-[4-[1-[4-[1-[6-[[3-acetyl-4-(3-amino-6-imino-4,5-disulfoxanthen-9-yl)benzoyl]amino]hexyl]triazol-4-yl]butyl]piperidin-4-yl]phenyl]-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	1953784: Antagonist activity at human P2Y14 expressed in CHO cells assessed as inhibition constant	ki	0.0001	uM
5-[(5-fluoro-2-pyridinyl)oxy]-4-[(4-methylbenzoyl)amino]thiophene-2-carboxylic acid	2085539: Antagonist activity at P2Y14R (unknown origin) stably expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production by cAMP-Glo assay	ic50	0.0004	uM
4-(4-piperidin-4-ylphenyl)-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	1626550: Antagonist activity human P2Y14R expressed in African green monkey COS7 cells assessed as inhibition of UDPG-induced [3H]inositol phosphate accumulation after 30 mins by liquid scintillation counting method	ic50	0.0004	uM
4-[(4-methylbenzoyl)amino]-5-[(5-methyl-2-pyridinyl)oxy]thiophene-2-carboxylic acid	2085539: Antagonist activity at P2Y14R (unknown origin) stably expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production by cAMP-Glo assay	ic50	0.0006	uM
N,N-diethylethanamine;[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid	444563: Agonist activity at human P2Y14 receptor expressed in HEK293 cells coexpressing phospholipase C-activating Gi protein cells assessed as inhibition of forskolin induced [3H]cAMP production	ec50	0.0009	uM
N-(3H-benzimidazol-5-yl)-2-[4-(hydroxymethyl)phenoxy]acetamide	2078095: Antagonist activity at human P2Y14R stably expressed in HEK293 cells assessed as inhibition of forskolin-reduced cAMP production incubated for 30 mins by cAMP-Glo assay	ic50	0.0011	uM
4-[(4-methoxybenzoyl)amino]-5-[(6-methyl-3-pyridinyl)oxy]thiophene-2-carboxylic acid	2085539: Antagonist activity at P2Y14R (unknown origin) stably expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production by cAMP-Glo assay	ic50	0.0013	uM
N-(3H-benzimidazol-5-yl)-2-(4-formylphenoxy)acetamide	2078095: Antagonist activity at human P2Y14R stably expressed in HEK293 cells assessed as inhibition of forskolin-reduced cAMP production incubated for 30 mins by cAMP-Glo assay	ic50	0.0013	uM
4-[4-[1-[4-[4-[(3’,6’-dihydroxy-3-oxospiro[2-benzofuran-1,9’-xanthene]-5-yl)carbamothioylamino]butanoylamino]butanoyl]piperidin-4-yl]phenyl]-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	2085539: Antagonist activity at P2Y14R (unknown origin) stably expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production by cAMP-Glo assay	ic50	0.0015	uM
3-[(4-methylbenzoyl)amino]-5-(4-piperidin-4-ylphenyl)benzoic acid	1564199: Antagonist activity at human P2Y14R stably expressed in human forskolin treated THP1 cells assessed as reduction in P2Y14R agonist UDPG-induced inhibition of cAMP production incubated for 15 mins by competitive enzyme-linked immunoassay	ic50	0.0018	uM
1-[(4-fluorophenyl)methyl]-5-[(4-methylbenzoyl)amino]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0019	uM
[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate	444563: Agonist activity at human P2Y14 receptor expressed in HEK293 cells coexpressing phospholipase C-activating Gi protein cells assessed as inhibition of forskolin induced [3H]cAMP production	ec50	0.0019	uM
N-(3H-benzimidazol-5-yl)-2-(4-chlorophenoxy)acetamide	2078095: Antagonist activity at human P2Y14R stably expressed in HEK293 cells assessed as inhibition of forskolin-reduced cAMP production incubated for 30 mins by cAMP-Glo assay	ic50	0.0019	uM
N-[3-(1,3-benzoxazol-2-yl)phenyl]-2-(4-methoxyphenyl)acetamide	1876617: Antagonist activity at human P2Y14R expressed in human HEK293 cells assessed as inhibition of cAMP level incubated for 30 mins by cAMP-glo assay	ic50	0.0020	uM
3-(furan-3-yl)-5-[(4-methylbenzoyl)amino]benzoic acid	1757151: Antagonist activity at P2Y14 (unknown origin) expressed in HEK293 cells assessed as reduction in cAMP production incubated for 30 mins by ADP-glo assay	ic50	0.0022	uM
3-[(4-methylbenzoyl)amino]-5-(1H-pyrazol-5-yl)benzoic acid	1757151: Antagonist activity at P2Y14 (unknown origin) expressed in HEK293 cells assessed as reduction in cAMP production incubated for 30 mins by ADP-glo assay	ic50	0.0026	uM
3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[(4-methylbenzoyl)amino]benzoic acid	1757151: Antagonist activity at P2Y14 (unknown origin) expressed in HEK293 cells assessed as reduction in cAMP production incubated for 30 mins by ADP-glo assay	ic50	0.0029	uM
4-[4-[(1S,4S,5S)-2-azabicyclo[2.2.1]heptan-5-yl]phenyl]-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	1822898: Inhibition of fluorescent antagonist binding to human P2Y14R expressed in CHO cells preincubated for 30 mins followed by 6-amino-9-(2-carboxy-4-((6-(4-(4-(4-(4-(3-carboxy 6-(4-(trifluoromethyl)phenyl)naphthalen-1-yl)phenyl)piperidin-1-yl)butyl)-1H-1,2,3-triazol-1-yl)hexyl)carbamoyl)phenyl)-3-iminio-5-sulfo-3H-xanthene-4-sulfonate addition and measured after 30 mins by BD FACSCalibur flow cytometry analysis	ic50	0.0031	uM
3-(4-piperidin-4-ylphenyl)-5-(pyridine-4-carbonylamino)benzoic acid	1564199: Antagonist activity at human P2Y14R stably expressed in human forskolin treated THP1 cells assessed as reduction in P2Y14R agonist UDPG-induced inhibition of cAMP production incubated for 15 mins by competitive enzyme-linked immunoassay	ic50	0.0032	uM
4-[4-[(1R,5S)-6-hydroxy-3-azabicyclo[3.1.1]heptan-6-yl]phenyl]-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	1982180: Displacement of fluorescent tracer 4-(4-(1-(4-(1-(6-(3-carboxylato-4-(3-iminio-3H-xanthen-9-yl)benzamido)hexyl)-4,5-dihydro-1H-pyrrol-3-yl)butyl)piperidin-1-ium-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoate from human P2Y14R stably expressed in CHO cells assessed as inhibition constant by flow cytometry	ki	0.0034	uM
5-[(4-methylbenzoyl)amino]-1-[[4-(trifluoromethyl)phenyl]methyl]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0038	uM
5-[(4-acetylbenzoyl)amino]-1-[(4-fluorophenyl)methyl]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0038	uM
N-(3H-benzimidazol-5-yl)-2-[4-(trifluoromethyl)phenoxy]acetamide	2078095: Antagonist activity at human P2Y14R stably expressed in HEK293 cells assessed as inhibition of forskolin-reduced cAMP production incubated for 30 mins by cAMP-Glo assay	ic50	0.0038	uM
5-[(4-methylbenzoyl)amino]-1-[(3,4,5-trifluorophenyl)methyl]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0040	uM
4-[(4-methylbenzoyl)amino]-5-(4-methylphenoxy)thiophene-2-carboxylic acid	2085539: Antagonist activity at P2Y14R (unknown origin) stably expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production by cAMP-Glo assay	ic50	0.0040	uM
2-(4-methylphenoxy)-N-quinolin-7-ylacetamide	2078095: Antagonist activity at human P2Y14R stably expressed in HEK293 cells assessed as inhibition of forskolin-reduced cAMP production incubated for 30 mins by cAMP-Glo assay	ic50	0.0040	uM
1-[(3,4-difluorophenyl)methyl]-5-[(4-methylbenzoyl)amino]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0042	uM
2-(4-methoxyphenoxy)-N-quinolin-7-ylacetamide	2078095: Antagonist activity at human P2Y14R stably expressed in HEK293 cells assessed as inhibition of forskolin-reduced cAMP production incubated for 30 mins by cAMP-Glo assay	ic50	0.0042	uM
3-(4-piperidin-4-ylphenyl)-5-(pyrazine-2-carbonylamino)benzoic acid	1564199: Antagonist activity at human P2Y14R stably expressed in human forskolin treated THP1 cells assessed as reduction in P2Y14R agonist UDPG-induced inhibition of cAMP production incubated for 15 mins by competitive enzyme-linked immunoassay	ic50	0.0043	uM
3-[(4-cyanobenzoyl)amino]-5-(4-piperidin-4-ylphenyl)benzoic acid	1564199: Antagonist activity at human P2Y14R stably expressed in human forskolin treated THP1 cells assessed as reduction in P2Y14R agonist UDPG-induced inhibition of cAMP production incubated for 15 mins by competitive enzyme-linked immunoassay	ic50	0.0045	uM
5-[(4-ethylbenzoyl)amino]-1-[(4-fluorophenyl)methyl]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0046	uM
1-[(4-cyanophenyl)methyl]-5-[(4-methylbenzoyl)amino]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0047	uM
N-[3-(1,3-benzoxazol-2-yl)phenyl]-2-[4-(trifluoromethoxy)phenyl]acetamide	1876617: Antagonist activity at human P2Y14R expressed in human HEK293 cells assessed as inhibition of cAMP level incubated for 30 mins by cAMP-glo assay	ic50	0.0048	uM
5-[(4-methylbenzoyl)amino]-1-[[2-(trifluoromethyl)phenyl]methyl]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0048	uM
3-[(4-methylbenzoyl)amino]-5-phenylbenzoic acid	1757151: Antagonist activity at P2Y14 (unknown origin) expressed in HEK293 cells assessed as reduction in cAMP production incubated for 30 mins by ADP-glo assay	ic50	0.0049	uM
3-benzamido-5-(4-piperidin-4-ylphenyl)benzoic acid	1564199: Antagonist activity at human P2Y14R stably expressed in human forskolin treated THP1 cells assessed as reduction in P2Y14R agonist UDPG-induced inhibition of cAMP production incubated for 15 mins by competitive enzyme-linked immunoassay	ic50	0.0050	uM
5-[(4-methylbenzoyl)amino]-1-[(4-nitrophenyl)methyl]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0050	uM
3-[(4-nitrobenzoyl)amino]-5-(4-piperidin-4-ylphenyl)benzoic acid	1564199: Antagonist activity at human P2Y14R stably expressed in human forskolin treated THP1 cells assessed as reduction in P2Y14R agonist UDPG-induced inhibition of cAMP production incubated for 15 mins by competitive enzyme-linked immunoassay	ic50	0.0051	uM
1-[(3-fluorophenyl)methyl]-5-[(4-methylbenzoyl)amino]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0054	uM
4-[4-[(3aR,6aR)-5-hydroxy-2,3,3a,4,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]phenyl]-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	1982180: Displacement of fluorescent tracer 4-(4-(1-(4-(1-(6-(3-carboxylato-4-(3-iminio-3H-xanthen-9-yl)benzamido)hexyl)-4,5-dihydro-1H-pyrrol-3-yl)butyl)piperidin-1-ium-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoate from human P2Y14R stably expressed in CHO cells assessed as inhibition constant by flow cytometry	ki	0.0055	uM
4-[4-(azepan-4-yl)phenyl]-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	1982180: Displacement of fluorescent tracer 4-(4-(1-(4-(1-(6-(3-carboxylato-4-(3-iminio-3H-xanthen-9-yl)benzamido)hexyl)-4,5-dihydro-1H-pyrrol-3-yl)butyl)piperidin-1-ium-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoate from human P2Y14R stably expressed in CHO cells assessed as inhibition constant by flow cytometry	ki	0.0056	uM
4-[4-(2-azaspiro[3.3]hept-6-en-6-yl)phenyl]-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid	1982180: Displacement of fluorescent tracer 4-(4-(1-(4-(1-(6-(3-carboxylato-4-(3-iminio-3H-xanthen-9-yl)benzamido)hexyl)-4,5-dihydro-1H-pyrrol-3-yl)butyl)piperidin-1-ium-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoate from human P2Y14R stably expressed in CHO cells assessed as inhibition constant by flow cytometry	ki	0.0056	uM
1-[(3,5-dimethylphenyl)methyl]-5-[(4-methylbenzoyl)amino]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0058	uM
N-[3-(5-chloro-1,3-benzoxazol-2-yl)phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide	1876617: Antagonist activity at human P2Y14R expressed in human HEK293 cells assessed as inhibition of cAMP level incubated for 30 mins by cAMP-glo assay	ic50	0.0061	uM
4-[(4-methylbenzoyl)amino]-5-(4-methylphenyl)sulfanylthiophene-2-carboxylic acid	2085539: Antagonist activity at P2Y14R (unknown origin) stably expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production by cAMP-Glo assay	ic50	0.0065	uM
4-[(4-methylbenzoyl)amino]-5-[(6-methyl-3-pyridinyl)oxy]thiophene-2-carboxylic acid	2085539: Antagonist activity at P2Y14R (unknown origin) stably expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production by cAMP-Glo assay	ic50	0.0065	uM
N-[3-(5-chloro-1,3-benzoxazol-2-yl)phenyl]-2-(4-methylphenyl)acetamide	1876617: Antagonist activity at human P2Y14R expressed in human HEK293 cells assessed as inhibition of cAMP level incubated for 30 mins by cAMP-glo assay	ic50	0.0067	uM
1-[(4-chlorophenyl)methyl]-5-[(4-methylbenzoyl)amino]pyrazole-3-carboxylic acid	1896866: Antagonist activity at P2Y14R (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated in presence of IBMX by cAMP-glo assay	ic50	0.0071	uM

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Progesterone	affects cotreatment, increases expression	3
Estradiol	affects cotreatment, increases expression	2
Tretinoin	increases expression	2
triphenyl phosphate	affects expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
tamibarotene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
Air Pollutants	affects expression, increases abundance	1
Allergens	increases expression	1
Cadmium	decreases expression, increases abundance	1
Lipopolysaccharides	increases expression, affects cotreatment, decreases expression, affects response to substance	1
Ozone	increases abundance, affects expression	1
Valproic Acid	decreases methylation	1
Mifepristone	increases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1

ChEMBL screening assays

101 unique, capped per target: 58 binding, 43 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1045264	Functional	Agonist activity at human P2Y14 receptor expressed in HEK293 cells coexpressing phospholipase C-activating Gi protein cells assessed as inhibition of forskolin induced [3H]cAMP production	Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5’-diphosphoglucose and its replacement with alkyl and aryl groups. — J Med Chem
CHEMBL2339544	Binding	Inhibition of human P2Y14 receptor	Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists. — J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_ZD97	1321N1-HA-P2Y14	Cancer cell line	Male
CVCL_ZK28	T-REx Tango P2RY14-bla U2OS	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.